Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Roivant Third Quarter 2025 Earnings Conference Call.
Immunovant Inc. (IMVT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 11,526,971 | $293,015,603 | +19% | 5.22% |
| 2. | Armistice Capital Steven Boyd | 5,747,155 | $146,092,680 | -2% | 1.74% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,457,881 | $138,739,335 | 0.81% | |
| 4. | Two Seas Capital Sina Toussi | 2,866,962 | $72,878,174 | +4% | 1.5% |
| 5. | ADAR1 Capital Management Daniel Schneeberger | 2,480,968 | $63,066,207 | +11% | 4.57% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.00 | 16,666,666 | $349,999,986.00 | 113,317,007 | 2025-12-12 | Filing | |
| $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | 2025-01-13 | Filing | |
| $38.00 | 1,526,316 | $58,000,008.00 | 79,805,331 | 2023-10-02 | Filing | |
| $6.00 | 416,667 | $2,500,002.00 | 73,805,331 | 2022-10-06 | Filing | |
| $5.60 | 15,000 | $84,000.00 | 20,000 | 2022-09-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.03 | 1,977 | $51,461.31 | 197,634 | 2026-01-21 | Filing | |
| $26.92 | 55 | $1,480.60 | 199,611 | 2026-01-07 | Filing | |
| $26.51 | 1,148 | $30,433.48 | 199,666 | 2026-01-07 | Filing | |
| $27.38 | 2,284 | $62,535.92 | 149,930 | 2025-12-18 | Filing | |
| $26.78 | 8,529 | $228,406.62 | 152,214 | 2025-12-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,990,754 | $431,904,967 | 0.02% | |
| 2. | 7,779,314 | $197,750,162 | 0% | |
| 3. | 6,058,216 | $153,999,851 | 0% | |
| 4. | 4,846,385 | $123,195,151 | 0.01% | |
| 5. | 3,786,926 | $96,263,659 | 0% |
News See All
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling
Immunovant Inc. (NASDAQ:IMVT) is one of the promising stocks to buy under $50.
10 Promising Stocks to Buy Under $50
On January 7, Jay Woods, Chief Market Strategist at Freedom Capital Markets, joined CNBC to state that stocks are broadening beyond tech, with materials, defense, transports, and airlines showing breakouts...
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings
Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now.
12 Best Short Squeeze Stocks to Buy Right Now
As the year comes to a close, investors are keeping close tabs on the Federal Reserve's impending policy move, given the US shutdown-induced data shortage.
Immunovant, Inc. (NASDAQ:IMVT) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to the Roivant Second Quarter 2025 Earnings Call. [Operator Instructions] Please note that today's conference is being recorded.
Immunovant, Inc. (NASDAQ:IMVT) Q2 2026 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to the Roivant Second Quarter 2025 Earnings Call. [Operator Instructions] Please note that today's conference is being recorded.
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results
According to Immunovant Inc. (NASDAQ:IMVT), it is set to announce the results of its financial and operating highlights before market open on November 10, 2025.
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37
Immunovant, Inc. (NASDAQ:IMVT) is one of the best biotech stocks with high potential. On September 30, JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant, Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Hedge Fund Resource Center Billionaire Hedge Funds
